Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 30 Billion KRW | -73.04% |
| 2022 | 111.29 Billion KRW | -17.54% |
| 2021 | 134.96 Billion KRW | 134.68% |
| 2020 | 57.5 Billion KRW | 122.51% |
| 2019 | 25.84 Billion KRW | -43.68% |
| 2018 | 45.89 Billion KRW | 114.87% |
| 2017 | 21.35 Billion KRW | -46.6% |
| 2016 | 40 Billion KRW | -43.34% |
| 2015 | 70.6 Billion KRW | 60.57% |
| 2014 | 43.96 Billion KRW | -27.92% |
| 2013 | 61 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 36.46 Billion KRW | -0.87% |
| 2024 Q1 | 36.78 Billion KRW | 22.63% |
| 2023 Q2 | 129.76 Billion KRW | 22.12% |
| 2023 Q1 | 106.25 Billion KRW | -4.52% |
| 2023 FY | 30 Billion KRW | -73.04% |
| 2023 Q4 | 30 Billion KRW | -14.76% |
| 2023 Q3 | 35.19 Billion KRW | -72.88% |
| 2022 Q3 | 114.23 Billion KRW | 0.47% |
| 2022 Q2 | 113.69 Billion KRW | -17.34% |
| 2022 FY | 111.29 Billion KRW | -17.54% |
| 2022 Q1 | 137.54 Billion KRW | 1.92% |
| 2022 Q4 | 111.29 Billion KRW | -2.57% |
| 2021 Q1 | 48.47 Billion KRW | -15.7% |
| 2021 Q4 | 134.96 Billion KRW | -7.78% |
| 2021 FY | 134.96 Billion KRW | 134.68% |
| 2021 Q3 | 146.34 Billion KRW | 210.74% |
| 2021 Q2 | 47.09 Billion KRW | -2.85% |
| 2020 Q2 | 48.95 Billion KRW | 106.65% |
| 2020 Q3 | 48.98 Billion KRW | 0.05% |
| 2020 FY | 57.5 Billion KRW | 122.51% |
| 2020 Q1 | 23.68 Billion KRW | -8.34% |
| 2020 Q4 | 57.5 Billion KRW | 17.41% |
| 2019 FY | 25.84 Billion KRW | -43.68% |
| 2019 Q1 | 58.17 Billion KRW | 26.75% |
| 2019 Q4 | 25.84 Billion KRW | -21.38% |
| 2019 Q3 | 32.87 Billion KRW | -1.35% |
| 2019 Q2 | 33.32 Billion KRW | -42.71% |
| 2018 Q2 | 26.52 Billion KRW | 12.96% |
| 2018 FY | 45.89 Billion KRW | 114.87% |
| 2018 Q4 | 45.89 Billion KRW | 77.3% |
| 2018 Q3 | 25.88 Billion KRW | -2.42% |
| 2018 Q1 | 23.48 Billion KRW | 9.95% |
| 2017 FY | 21.35 Billion KRW | -46.6% |
| 2017 Q4 | 21.35 Billion KRW | 0.0% |
| 2016 Q2 | 70.6 Billion KRW | 0.0% |
| 2016 Q1 | 70.6 Billion KRW | 0.0% |
| 2016 FY | 40 Billion KRW | -43.34% |
| 2016 Q3 | 70.6 Billion KRW | 0.0% |
| 2015 Q2 | 38.6 Billion KRW | 26.14% |
| 2015 Q4 | 70.6 Billion KRW | 82.9% |
| 2015 Q1 | 30.6 Billion KRW | -30.4% |
| 2015 Q3 | 38.6 Billion KRW | 0.0% |
| 2015 FY | 70.6 Billion KRW | 60.57% |
| 2014 Q2 | 57.36 Billion KRW | -22.86% |
| 2014 Q1 | 74.36 Billion KRW | 0.0% |
| 2014 Q3 | 57.36 Billion KRW | 0.0% |
| 2014 FY | 43.96 Billion KRW | -27.92% |
| 2014 Q4 | 43.96 Billion KRW | -23.36% |
| 2013 FY | 61 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.941% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 85.153% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -0.413% |
| HANDOK Inc. | 123.78 Billion KRW | 75.764% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -6205.928% |
| Yuhan Corporation | 60.23 Billion KRW | 50.194% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 81.481% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -29364.399% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 63.427% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -4982.082% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -395.868% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -61.966% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -138.394% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -1776.353% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.941% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -24967.18% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 75.207% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 6.25% |
| JW Holdings Corporation | 20.65 Billion KRW | -45.227% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -102.358% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 0.0% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -13601.07% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -5066.658% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 39.478% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -573.854% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -119.941% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -57.665% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 67.885% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 0.0% |
| Yuhan Corporation | 60.23 Billion KRW | 50.194% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -185.714% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 25.702% |
| Suheung Co., Ltd. | 74 Billion KRW | 59.463% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -620.005% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -173.66% |
| CKD Bio Corp. | 69.43 Billion KRW | 56.792% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 13.232% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -86.016% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -9670.198% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -13601.07% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 58.398% |
| Boryung Corporation | 151.7 Billion KRW | 80.225% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 61.796% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -395.868% |
| JW Lifescience Corporation | 168 Million KRW | -17757.143% |